Apricus Biosciences Inc (NASDAQ:APRI) traded down 5.5% on Thursday . The company traded as low as $2.20 and last traded at $2.25. 835,806 shares were traded during trading, an increase of 5% from the average session volume of 795,837 shares. The stock had previously closed at $2.38.

A number of equities research analysts recently weighed in on the company. HC Wainwright set a $5.00 price target on Apricus Biosciences and gave the company a “buy” rating in a report on Tuesday, January 16th. Zacks Investment Research cut Apricus Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, January 23rd. Finally, ValuEngine raised Apricus Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.

The company has a market cap of $34.24, a P/E ratio of 3.98 and a beta of 0.38.

An institutional investor recently bought a new position in Apricus Biosciences stock. Healthcare Value Capital LLC acquired a new position in shares of Apricus Biosciences Inc (NASDAQ:APRI) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 100,000 shares of the company’s stock, valued at approximately $184,000. Apricus Biosciences accounts for about 0.6% of Healthcare Value Capital LLC’s investment portfolio, making the stock its 8th largest holding. Healthcare Value Capital LLC owned approximately 0.66% of Apricus Biosciences as of its most recent SEC filing. Institutional investors own 24.01% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Apricus Biosciences (APRI) Trading Down 5.5%” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/apricus-biosciences-apri-trading-down-5-5/1858079.html.

About Apricus Biosciences

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

Receive News & Ratings for Apricus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.